Human and murine oprm1 promoters and uses thereof
AssigneesThe Trustees of the University of Pennsylvania, The Board of Trustees of the Leland Stanford Junior University
InventorsGregory Corder, Gregory Salimando, Karl Deisseroth, Charu Ramakrishnan
Life of this patent
Estimating the term…
Abstract
The disclosure relates to isolated nucleic acids comprising opioid receptor promoter regions and methods and compositions comprising said isolated nucleic acids. In one aspect the invention provides an isolated nucleic acid comprising a first region that encodes a Opioid Receptor promoter (ORP) region operably linked to a second region encoding an exogenous protein; wherein the opioid receptor promoter is selected from the group consisting of a mu opioid receptor promoter (MORP), a delta opioid receptor promoter (DORP), and a kappa opioid receptor promoter (KORP).
Claims41
An isolated nucleic acid comprising a first region that encodes a Opioid Receptor promoter (ORP) region operably linked to a second region encoding an exogenous protein;
- wherein the opioid receptor promoter is selected from the group consisting of a mu opioid receptor promoter (MORP), a delta opioid receptor promoter (DORP), and a kappa opioid receptor promoter (KORP).
A method of providing analgesia to a subject in need thereof, comprising:
- a. administering to the subject an effective amount of a composition comprising a recombinant AAV vector comprising an isolated nucleic acid comprising a first region encoding a ORP region operably linked to a second region encoding a designer receptor exclusively activated by a designer drug (DREADD),
- wherein the DREADD is expressed by cells of the central nervous system;
- and
- b. administering to the subject an effective amount of an agonist capable of engaging and activating the DREADD of part a., thereby providing analgesia,
- wherein the ORP region is selected from the group consisting of a MORP region, a DORP region, and a KORP region.
Dependencies are inferred from the claim text.